Raymond James Raises Charles River Laboratories Intl. (CRL) Price Target to $150.00

Charles River Laboratories Intl. (NYSE:CRL) had its target price boosted by Raymond James from $140.00 to $150.00 in a research report released on Thursday morning, Marketbeat Ratings reports. Raymond James currently has a buy rating on the medical research company’s stock.

CRL has been the subject of a number of other reports. Credit Suisse Group boosted their target price on Charles River Laboratories Intl. from $121.00 to $128.00 and gave the company a neutral rating in a research report on Tuesday, September 25th. Jefferies Financial Group reaffirmed a buy rating and issued a $140.00 target price on shares of Charles River Laboratories Intl. in a research report on Friday, July 20th. ValuEngine downgraded Charles River Laboratories Intl. from a buy rating to a hold rating in a research note on Wednesday, October 24th. Royal Bank of Canada set a $147.00 price target on Charles River Laboratories Intl. and gave the company a buy rating in a research note on Wednesday. Finally, Argus lifted their price target on Charles River Laboratories Intl. from $125.00 to $140.00 and gave the company a buy rating in a research note on Monday, August 27th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $130.56.

Charles River Laboratories Intl. stock traded up $0.35 during midday trading on Thursday, reaching $136.45. The stock had a trading volume of 587,848 shares, compared to its average volume of 372,070. Charles River Laboratories Intl. has a 12 month low of $96.70 and a 12 month high of $138.89. The firm has a market capitalization of $6.01 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.57 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating analysts’ consensus estimates of $1.38 by $0.15. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The business had revenue of $585.30 million during the quarter, compared to analyst estimates of $567.58 million. During the same period in the previous year, the company posted $1.30 EPS. The firm’s revenue was up 26.1% compared to the same quarter last year. On average, sell-side analysts expect that Charles River Laboratories Intl. will post 5.91 EPS for the current year.

In other news, insider David P. Johst sold 23,356 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $136.00, for a total value of $3,176,416.00. Following the transaction, the insider now owns 219,849 shares in the company, valued at approximately $29,899,464. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Deborah Turner Kochevar sold 4,066 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total value of $502,801.56. Following the completion of the transaction, the director now owns 10,190 shares in the company, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. Insiders have sold a total of 28,671 shares of company stock valued at $3,829,160 in the last quarter. Company insiders own 2.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. First Trust Advisors LP boosted its stake in shares of Charles River Laboratories Intl. by 56.7% in the 3rd quarter. First Trust Advisors LP now owns 858,962 shares of the medical research company’s stock worth $115,565,000 after buying an additional 310,975 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Charles River Laboratories Intl. by 7.0% in the 2nd quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock worth $499,216,000 after purchasing an additional 292,685 shares during the period. Bank of Montreal Can raised its holdings in shares of Charles River Laboratories Intl. by 1,910.1% in the 3rd quarter. Bank of Montreal Can now owns 221,355 shares of the medical research company’s stock worth $29,781,000 after purchasing an additional 210,343 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Charles River Laboratories Intl. by 51.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 396,451 shares of the medical research company’s stock worth $53,339,000 after purchasing an additional 134,594 shares during the period. Finally, Monarch Partners Asset Management LLC bought a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter worth approximately $14,587,000. Hedge funds and other institutional investors own 96.93% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Stock Symbol

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply